Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mangiferonic acid is a cycloartane-type triterpenoid primarily isolated from plants in the genus *Mangifera*, such as the common mango (*Mangifera indica*) and the Bambangan (*Mangifera pajang*). It is a bioactive phytochemical that has demonstrated a range of pharmacological activities in preclinical studies, including antioxidant, anti-inflammatory, and anti-diabetic effects. Specifically, it has been investigated for its ability to inhibit alpha-glucosidase, suggesting potential utility in managing postprandial hyperglycemia. Additionally, mangiferonic acid has shown cytotoxic properties against several cancer cell lines, including breast and colon cancer, potentially through the induction of apoptosis and inhibition of NF-kappaB signaling pathways. It is currently categorized as a nutraceutical or research compound rather than an approved pharmaceutical agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mangiferonic acid.